CA3212745A1 - Formulation de cannabinoide pour la gestion de la depression, de l?anxiete et du tspt, et formulation de cannabinoide comme aide au sommeil - Google Patents
Formulation de cannabinoide pour la gestion de la depression, de l?anxiete et du tspt, et formulation de cannabinoide comme aide au sommeil Download PDFInfo
- Publication number
- CA3212745A1 CA3212745A1 CA3212745A CA3212745A CA3212745A1 CA 3212745 A1 CA3212745 A1 CA 3212745A1 CA 3212745 A CA3212745 A CA 3212745A CA 3212745 A CA3212745 A CA 3212745A CA 3212745 A1 CA3212745 A1 CA 3212745A1
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- cbd
- cbc
- primary
- thc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 210
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 210
- 239000000203 mixture Substances 0.000 title claims abstract description 210
- 238000009472 formulation Methods 0.000 title claims abstract description 200
- 230000007958 sleep Effects 0.000 title claims abstract description 62
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 59
- 230000036506 anxiety Effects 0.000 title claims abstract description 56
- 229950011318 cannabidiol Drugs 0.000 claims abstract description 193
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims abstract description 192
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims abstract description 192
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims abstract description 192
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims abstract description 192
- 229940065144 cannabinoids Drugs 0.000 claims abstract description 129
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 121
- 229960004242 dronabinol Drugs 0.000 claims abstract description 119
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims abstract description 117
- 208000028173 post-traumatic stress disease Diseases 0.000 claims abstract description 54
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 35
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 21
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 16
- 206010022437 insomnia Diseases 0.000 claims abstract description 16
- 239000003921 oil Substances 0.000 claims description 49
- 239000002775 capsule Substances 0.000 claims description 48
- 239000007788 liquid Substances 0.000 claims description 28
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 claims description 23
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 22
- 239000002552 dosage form Substances 0.000 claims description 19
- 239000006187 pill Substances 0.000 claims description 17
- 239000007921 spray Substances 0.000 claims description 16
- 230000004630 mental health Effects 0.000 claims description 14
- 239000006188 syrup Substances 0.000 claims description 14
- 235000020357 syrup Nutrition 0.000 claims description 14
- 230000000926 neurological effect Effects 0.000 claims description 8
- 206010029412 Nightmare Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 33
- 230000035882 stress Effects 0.000 description 32
- 238000012048 forced swim test Methods 0.000 description 29
- 238000012360 testing method Methods 0.000 description 29
- 230000000694 effects Effects 0.000 description 27
- 230000001430 anti-depressive effect Effects 0.000 description 23
- 239000000499 gel Substances 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 16
- 238000007726 management method Methods 0.000 description 16
- 239000000284 extract Substances 0.000 description 14
- 230000000996 additive effect Effects 0.000 description 13
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 12
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 12
- 241000218236 Cannabis Species 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 11
- 238000012346 open field test Methods 0.000 description 11
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 10
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 10
- 239000000654 additive Substances 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 239000002249 anxiolytic agent Substances 0.000 description 9
- 238000011725 BALB/c mouse Methods 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 230000000949 anxiolytic effect Effects 0.000 description 7
- 230000003542 behavioural effect Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000007267 depressive like behavior Effects 0.000 description 7
- 230000009429 distress Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000020401 Depressive disease Diseases 0.000 description 6
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 6
- 230000000049 anti-anxiety effect Effects 0.000 description 6
- 239000000935 antidepressant agent Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000001270 agonistic effect Effects 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 4
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 208000011688 Generalised anxiety disease Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 4
- 108010025083 TRPV1 receptor Proteins 0.000 description 4
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 4
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 4
- 238000011278 co-treatment Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000002621 endocannabinoid Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000029364 generalized anxiety disease Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 3
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010041250 Social phobia Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000037326 chronic stress Effects 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000003001 depressive effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 208000019906 panic disease Diseases 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 208000019899 phobic disease Diseases 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 208000022925 sleep disturbance Diseases 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- -1 CBC Chemical compound 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 2
- 108050007331 Cannabinoid receptor Proteins 0.000 description 2
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 2
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000013200 Stress disease Diseases 0.000 description 2
- 102000012253 TRPA1 Cation Channel Human genes 0.000 description 2
- 108010036769 TRPA1 Cation Channel Proteins 0.000 description 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 230000007529 anxiety like behavior Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000009227 behaviour therapy Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000018180 degenerative disc disease Diseases 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000003957 neurotransmitter release Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000009520 phase I clinical trial Methods 0.000 description 2
- 230000000506 psychotropic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000006200 vaporizer Substances 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- 208000025940 Back injury Diseases 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016352 Feeling of relaxation Diseases 0.000 description 1
- 102000017911 HTR1A Human genes 0.000 description 1
- 101150015707 HTR1A gene Proteins 0.000 description 1
- 206010048533 Hypervigilance Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102000009855 Inwardly Rectifying Potassium Channels Human genes 0.000 description 1
- 108010009983 Inwardly Rectifying Potassium Channels Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102100029814 Monoglyceride lipase Human genes 0.000 description 1
- 101710116393 Monoglyceride lipase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000028373 Neck injury Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000003556 cannabinoid 2 receptor agonist Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000007357 depressive behavior Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 210000005215 presynaptic neuron Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000013285 stress animal model Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formulations et procédés de gestion de la dépression, de l?anxiété et/ou du TSPT, pour l?utilisation chez des personnes en ayant besoin. Les formulations comprennent une pluralité de cannabinoïdes et un ou plusieurs excipients, diluants ou supports. Les cannabinoïdes sont présents dans la formulation en quantités optimisées pour traiter ces états en une quantité de : tétrahydrocannabinol (THC), cannabichromène (CBC), et cannabidiol (CBD) comme cannabinoïdes primaires sous un rapport en poids de 0 à 1:4 à 20:10 à 25, respectivement, tel que de 1:5:20, 0:20:10 ou 0:10:20. L?invention concerne également des formulations et des procédés d?aide au sommeil, pour l?utilisation par des personnes en ayant besoin, telles que des personnes atteintes d?insomnie. La formulation comprend une pluralité de cannabinoïdes et un ou plusieurs excipients, diluants ou supports. La formulation comprend du tétrahydrocannabinol (THC), du cannabichromène (CBC), et du cannabidiol (CBD) comme cannabinoïdes primaires sous un rapport en poids de 1:0 à 5:15 à 25, respectivement, tel que de 1:3:20, 1:0:20 ou 1:4:20.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163168868P | 2021-03-31 | 2021-03-31 | |
| US63/168,868 | 2021-03-31 | ||
| PCT/CA2021/051602 WO2022204782A1 (fr) | 2021-03-31 | 2021-11-10 | Formulation de cannabinoïde pour la gestion de la dépression, de l'anxiété et du tspt, et formulation de cannabinoïde comme aide au sommeil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3212745A1 true CA3212745A1 (fr) | 2022-10-06 |
Family
ID=88069125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3212745A Pending CA3212745A1 (fr) | 2021-03-31 | 2021-11-10 | Formulation de cannabinoide pour la gestion de la depression, de l?anxiete et du tspt, et formulation de cannabinoide comme aide au sommeil |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA3212745A1 (fr) |
-
2021
- 2021-11-10 CA CA3212745A patent/CA3212745A1/fr active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | The benefits of hesperidin in central nervous system disorders, based on the neuroprotective effect | |
| US10369182B2 (en) | Compositions and methods for treating insomnia and other sleep related disorders | |
| CA2656698C (fr) | Cannabinoides destines a etre utilises dans le traitement de la douleur nevropathique | |
| Hosseini et al. | Diabetic neuropathy and oxidative stress: therapeutic perspectives | |
| US7968594B2 (en) | Pharmaceutical compositions for the treatment of pain | |
| WO2019224824A1 (fr) | Compositions à base de cannabis pour le traitement de troubles du spectre autistique | |
| EP3215148B1 (fr) | Utilisation de faible dose de tetrahydrocannabinol pour le traitement du déclin cognitif chez les patients âgés | |
| Bedlack et al. | Complementary and alternative therapies in ALS | |
| Neis et al. | Depressive-like behavior induced by tumor necrosis factor-α is abolished by agmatine administration | |
| WO2020115751A1 (fr) | Compositions à base de cannabis pour le traitement de la maladie d'alzheimer et de la démence | |
| US20230321121A1 (en) | Opioid sparing formulation for pain management | |
| CA3200651A1 (fr) | Compositions anti-inflammatoires comprenant du cannabidiol, du delta-9-tetrahydrocannabinol et du linalool | |
| Sic et al. | The role of phytochemicals in managing neuropathic pain: how much progress have we made? | |
| US20240173339A1 (en) | Cannabinoid formulation for management of depression, anxiety and ptsd, and cannabinoid formulation as a sleep aid | |
| Zulkifli et al. | Exploring honey's potential as a functional food for natural sleep aid | |
| CA3212745A1 (fr) | Formulation de cannabinoide pour la gestion de la depression, de l?anxiete et du tspt, et formulation de cannabinoide comme aide au sommeil | |
| Balter et al. | The synthetic analog of Δ9-tetrahydrocannabinol (THC): Nabilone. Pharmacology and clinical application | |
| US9415064B2 (en) | Prevention or treatment of painful polyneuropathies by administration of an aluminosilicate | |
| US11963943B2 (en) | Formulation for pain management | |
| Schell | Sceletium tortuosum and mesembrine: a potential alternative treatment for depression | |
| DK2900253T3 (en) | PROCEDURE FOR RELIEFING MULTIPLE SCLEROSE SYMPTOMS BASED ON APOAEQUORIN-CONTAINING COMPOSITIONS | |
| Serafimovska et al. | Approved indications for cannabis-based preparations | |
| Li et al. | Citrus aurantium L. extract alleviate depression by inhibiting gut microbiota-mediated inflammation in mice | |
| Mandici et al. | Cannabis therapy in neurological disorders: Recent advances and perspectives | |
| IT202300000618A1 (it) | Associazione di principi attivi, composizioni che la contengono e loro uso per lenire e/o contrastare i disturbi causati da ansia e stress |